CA3079374A1 - Treatment of cd20-positive b-cell lymphoma with obituzumab - Google Patents

Treatment of cd20-positive b-cell lymphoma with obituzumab Download PDF

Info

Publication number
CA3079374A1
CA3079374A1 CA3079374A CA3079374A CA3079374A1 CA 3079374 A1 CA3079374 A1 CA 3079374A1 CA 3079374 A CA3079374 A CA 3079374A CA 3079374 A CA3079374 A CA 3079374A CA 3079374 A1 CA3079374 A1 CA 3079374A1
Authority
CA
Canada
Prior art keywords
obinutuzumab
hour
cycle
administration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3079374A
Other languages
English (en)
French (fr)
Inventor
Michael Wenger
Mehrdad Mobasher
Chin-Yu Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3079374(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA3079374A1 publication Critical patent/CA3079374A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
CA3079374A 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obituzumab Pending CA3079374A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
US62/574,297 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
CA3079374A1 true CA3079374A1 (en) 2019-01-24

Family

ID=64362606

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3079374A Pending CA3079374A1 (en) 2017-10-19 2018-10-19 Treatment of cd20-positive b-cell lymphoma with obituzumab

Country Status (14)

Country Link
US (2) US12129304B2 (OSRAM)
EP (2) EP4520347A3 (OSRAM)
JP (2) JP6860652B2 (OSRAM)
KR (2) KR20240157135A (OSRAM)
CN (2) CN111212854A (OSRAM)
AU (2) AU2018303836B2 (OSRAM)
BR (1) BR112020007731A2 (OSRAM)
CA (1) CA3079374A1 (OSRAM)
ES (1) ES3005784T3 (OSRAM)
IL (2) IL321935A (OSRAM)
MX (2) MX419643B (OSRAM)
PL (1) PL3697818T3 (OSRAM)
TW (2) TWI828593B (OSRAM)
WO (1) WO2019017499A2 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240157135A (ko) * 2017-10-19 2024-10-31 에프. 호프만-라 로슈 아게 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료
WO2021065568A1 (ja) * 2019-10-04 2021-04-08 中外製薬株式会社 オビヌツズマブ耐性ｃｄ２０陽性癌の細胞の増殖を抑制する剤、ならびにそれに関連する医薬組成物、医薬、製造、細胞の増殖を抑制する方法、治療方法、ｉｉ型抗ｃｄ２０抗体、化合物、およびそれらの組み合わせ、増強剤および誘導剤
EP4404430A4 (en) 2021-09-17 2025-10-29 Canon Kk POWER TRANSMISSION DEVICE AND POWER RECEPTION DEVICE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4653109B2 (ja) 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
DK2234600T3 (da) * 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
DK3179992T3 (da) * 2014-08-11 2022-07-11 Acerta Pharma Bv Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
WO2019017449A1 (ja) 2017-07-21 2019-01-24 横浜ゴム株式会社 空気入りタイヤ
KR20240157135A (ko) * 2017-10-19 2024-10-31 에프. 호프만-라 로슈 아게 오비누투주맙에 의한 cd20-양성 b 세포 림프종의 치료

Also Published As

Publication number Publication date
PL3697818T3 (pl) 2025-03-24
MX2020003418A (es) 2020-07-20
EP3697818A2 (en) 2020-08-26
BR112020007731A2 (pt) 2020-10-20
JP7370357B2 (ja) 2023-10-27
CN120983618A (zh) 2025-11-21
MX2024009217A (es) 2024-11-08
IL273909A (en) 2020-05-31
JP2019528282A (ja) 2019-10-10
EP4520347A2 (en) 2025-03-12
EP4520347A3 (en) 2025-06-04
JP2021152002A (ja) 2021-09-30
KR20240157135A (ko) 2024-10-31
MX419643B (es) 2025-01-14
CN111212854A (zh) 2020-05-29
AU2025205481A1 (en) 2025-08-07
US20250026847A1 (en) 2025-01-23
TW202342099A (zh) 2023-11-01
IL321935A (en) 2025-09-01
KR102766089B1 (ko) 2025-02-13
AU2018303836A1 (en) 2020-05-14
JP6860652B2 (ja) 2021-04-21
US12129304B2 (en) 2024-10-29
EP3697818B1 (en) 2024-11-27
TWI828593B (zh) 2024-01-01
TW201922284A (zh) 2019-06-16
AU2018303836B2 (en) 2025-04-17
ES3005784T3 (en) 2025-03-17
IL273909B2 (en) 2025-12-01
US20200299398A1 (en) 2020-09-24
KR20200067196A (ko) 2020-06-11
TWI805630B (zh) 2023-06-21
WO2019017499A2 (en) 2019-01-24
IL273909B1 (en) 2025-08-01
WO2019017499A3 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
US20250026847A1 (en) Treatment of cd20-positive b-cell lymphoma with obinutuzumab
US20250074979A1 (en) Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
AU2021298106A1 (en) Anti-tumor combination therapy comprising anti-CD19 antibody and polypeptides blocking the SIRPalpha-CD47 innate immune checkpoint
HK40031517A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
EP2058332A1 (en) Use of CD25 binding molecules in steroid-resistant patients
US20220339174A1 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
JP2025501238A (ja) Ｉｌ－７タンパク質とｖｅｇｆアンタゴニストの併用による腫瘍の治療方法
TW202402791A (zh) 抗ｉｌ－２７抗體之用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230922